Vestronidase Alfa-vjbk Injection (MEPSEVII)

MEPSEVII (vestronidase alfa‑vjbk) is covered for pediatric and adult treatment of FDA‑approved Mucopolysaccharidosis VII (Sly syndrome) but not when used primarily to treat CNS manifestations, and no off‑label compendial uses are approved. Coverage requires confirmation by β‑glucuronidase enzyme assay or genetic testing, documentation of FDA‑approved indication, dosing at 4 mg/kg IV every 2 weeks, availability of anaphylaxis support at administration, and approvals are issued for up to 12 months.

"MEPSEVII is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome)."

Sign up to see full coverage criteria, indications, and limitations.